dc.contributor.author | Aligholipour Farzani, Touraj | |
dc.contributor.author | Földes, Katalin | |
dc.contributor.author | Hanifehnezhad, Alireza | |
dc.contributor.author | Yener Ilce, Burcu | |
dc.contributor.author | Bilge Dagalp, Seval | |
dc.contributor.author | Amirzadeh Khiabani, Neda | |
dc.contributor.author | Ergünay, Koray | |
dc.contributor.author | Alkan, Feray | |
dc.contributor.author | Karaoglu, Taner | |
dc.contributor.author | Bodur, Hurrem | |
dc.contributor.author | Ozkul, Aykut | |
dc.date.accessioned | 2021-06-03T06:03:32Z | |
dc.date.available | 2021-06-03T06:03:32Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 1999-4915 | |
dc.identifier.uri | http://dx.doi.org/10.3390/v11030237 | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466008/ | |
dc.identifier.uri | http://hdl.handle.net/11655/24194 | |
dc.description.abstract | Crimean-Congo hemorrhagic fever virus (CCHFV) is the causative agent of a tick-borne infection with a significant mortality rate of up to 40% in endemic areas, with evidence of geographical expansion. Due to a lack of effective therapeutics and control measures, the development of a protective CCHFV vaccine remains a crucial public health task. This paper describes, for the first time, a Bovine herpesvirus type 4 (BoHV-4)-based viral vector (BoHV4-∆TK-CCHFV-N) and its immunogenicity in BALB/c and protection potential in IFNα/β/γR−/− mice models in comparison with two routinely used vaccine platforms, namely, Adenovirus type 5 and a DNA vector (pCDNA3.1 myc/His A), expressing the same antigen. All vaccine constructs successfully elicited significantly elevated cytokine levels and specific antibody responses in immunized BALB/c and IFNα/β/γR−/− mice. However, despite highly specific antibody responses in both animal models, the antibodies produced were unable to neutralize the virus in vitro. In the challenge experiment, only the BoHV4-∆TK-CCHFV-N and Ad5-N constructs produced 100% protection against lethal doses of the CCHFV Ank-2 strain in IFNα/β/γR−/− mice. The delivery platforms could not be compared due to similar protection rates in IFNα/β/γR−/− mice. However, during the challenge experiment in the T cell and passive antibody transfer assay, BoHV4-∆TK-CCHFV-N was dominant, with a protection rate of 75% compared to others. In conclusion, vector-based CCHFV N protein expression constitutes an effective approach for vaccine development and BoHV-4 emerged as a strong alternative to previously used viral vectors. | |
dc.language.iso | en | |
dc.relation.isversionof | 10.3390/v11030237 | |
dc.rights | Attribution 4.0 United States | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Bovine Herpesvirus Type 4 (Bohv-4) Vector Delivering Nucleocapsid Protein Of Crimean-Congo Hemorrhagic Fever Virus Induces Comparable Protective Immunity Against Lethal Challenge In Ifnα/Β/Γr−/− Mice Models | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Viruses | |
dc.contributor.department | Tıbbi Mikrobiyoloji | |
dc.identifier.volume | 11 | |
dc.identifier.issue | 3 | |
dc.description.index | PubMed | |
dc.description.index | WoS | |
dc.description.index | Scopus | |